an effective amount of a monoclonal autoantibody selected from the group consisting of mAb SCH 94.03, SCH 79.08, O1, O4, A2B5, HNK-1, [active] antigen binding fragments thereof, and [natural] isolated or synthetic autoantibodies having the characteristics thereof.

9. (Amended) A method of treating a demyelinating disease of the central nervous system in a mammal in need of such therapy which comprises administering to said mammal an effective amount of a monoclonal autoantibody selected from the group consisting of mAb SCH94.03, SCH79.08, O1, O4, A2B5 and HNK-1, [active] antigen binding fragments thereof, and [natural] isolated or synthetic autoantibodies having the characteristics thereof.

19. (Amended) A pharmaceutical composition comprising, as the active agent, an [active] antigen binding fragment of a monoclonal autoantibody selected from the group consisting of mAb SCH94.03, SCH79.08, [O1, O4, A2B5,] HNK-1, and [natural] isolated or synthetic autoantibodies having the characteristics of mAb SCH94.03, SCH79.08, O1, O4, A2B5 or HNK-1.

REMARKS

The foregoing amendments and the following remarks are submitted in response to the Office action mailed October 2, 1997.

The Examiner has requested that Applicants update the U.S. application for which this application claims priority to under § 120. Applicants have amended the priority to reflect issuance of the priority application, USSN 08/236,520 as U.S. Patent 5,591,629.

Status of the Claims

Claims 1-4, 9-14 and 19 are pending in the application. Claims 1, 9 and 19 have been amended, in order to more particularly point out and distinctly claim that which Applicants regard as the invention. Support for amended Claims 1, 9 and 19 can be found generally